A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Completed · Phase 1 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus Infections

In brief

The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.

Key facts

Study ID

NCT06573281

Run by

GlaxoSmithKline

People needed

213

Starts

2024-09-30

Expected to finish

2026-02-26

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits).
• Written informed consent obtained from the participant prior to performance of any study-specific procedure.
• Healthy participants as established by medical history, clinical examination and laboratory assessment at screening.
• Male or female between and including 18 and 45 years of age at the time of enrollment into the study.
• Body mass index more than or equal to (>=) 18 kg/m\^2 and less than (<) 40 kg/m\^2.
• Female participants of non-childbearing potential may be enrolled in the study.
• Female participants of childbearing potential may be enrolled in the study if the participant:
• has practiced adequate contraception for 1 month prior to study intervention administration period, and
• has a negative pregnancy test (on urine sample) on the day of study intervention administration, and
• has agreed to continue adequate contraception during the entire treatment period and for at least 1 month after completion of the study intervention administration series.

You may not qualify if…

• Medical conditions
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
• Hypersensitivity to latex.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
• Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.
• Recurrent history or uncontrolled neurological disorders or seizures.
• Documented HIV, HBV, or HCV-positive participant.
• Lymphoproliferative disorder or malignancy within 5 years before the first dose of study intervention administration.
• History of or current suspicion of myocarditis or pericarditis.
• Prior/Concomitant therapy
• Use of any investigational or non-registered product (drug, vaccine, or invasive medical device) other than the study intervention during the period beginning 30 days before the first dose of study intervention administration (Day -29 to Day 1), or their planned use during the study period.
• Has previously received an investigational or approved vaccine or antibody for prevention of RSV infection.
• Planned administration/administration of a vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention administration, except for inactivated vaccines for influenza if they are received at least 14 days before the first dose or 14 days after the last study intervention administration.
• Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
• Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).
• Other exclusion criteria
• Pregnant or lactating female participant.
• Female participant planning to become pregnant or planning to discontinue contraceptive precautions within 1 month following the last study intervention administration.
• Alcoholism or substance use disorder within the past 24 months.
• Any study personnel or their immediate dependents, family, or household members.
• Participants with extensive body markings or conditions in the deltoid region that may preclude accurate assessment of local reactogenicity.

Where it is running

• GSK Investigational Site — Rolling Hills Estates, California, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Lenexa, Kansas, United States
• GSK Investigational Site — Omaha, Nebraska, United States
• GSK Investigational Site — Rochester, New York, United States
• GSK Investigational Site — Camberwell, Victoria, Australia
• GSK Investigational Site — Madrid, Spain
• GSK Investigational Site — Madrid, Spain
• GSK Investigational Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.